← Back to patent-cliff list
Honokiol liposome lyophilized powder for injection (Jinrui Foundation)
Tier C — Watch / tradeHonokiol liposome lyophilized powder for injection (Jinrui Foundation)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Natural product / extract
Type
Targets：FOXM1
Indications (approved)：Glioblastoma, Meningioma, Solid tumour, Non-small cell lung cancer
Regional status
US
-
EU
-
China
Phase II
2024-10-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Honokiol liposome lyophilized powder for injection (Jinrui Foundation)?
Approved indications include: Glioblastoma, Meningioma, Solid tumour, Non-small cell lung cancer.
When does the Honokiol liposome lyophilized powder for injection (Jinrui Foundation) patent expire?
No public expiry year is available for Honokiol liposome lyophilized powder for injection (Jinrui Foundation) yet; this page updates once verified.
How do I get a quote for Honokiol liposome lyophilized powder for injection (Jinrui Foundation) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01